Related references
Note: Only part of the references are listed.Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score
Jochen G. Mainz et al.
FRONTIERS IN PHARMACOLOGY (2022)
Use of proton pump inhibitors is associated with lower hemoglobin levels in people with cystic fibrosis
Alex H. Gifford et al.
PEDIATRIC PULMONOLOGY (2021)
Eating disorders and body image in cystic fibrosis
Amy Darukhanavala et al.
JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY (2021)
Screening strategy for gastrointestinal and hepatopancreatobiliary cancers in cystic fibrosis
Brett Hoskins et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)
Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis The SIMPLIFY Clinical Trial Study Design
Nicole Mayer-Hamblett et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2021)
Prevalence of Malnutrition in Pediatric Hospitals in Developed and In-Transition Countries: The Impact of Hospital Practices
Andrea McCarthy et al.
NUTRIENTS (2019)
Adverse Effects of Proton Pump Inhibitors-Evidence and Plausibility
Reidar Fossmark et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Beyond the expected: Identifying broad research priorities of researchers and the cystic fibrosis community
I. L. Hollin et al.
JOURNAL OF CYSTIC FIBROSIS (2019)
Cystic fibrosis is associated with an increased risk of Barrett's esophagus
Rita M. Knotts et al.
JOURNAL OF CYSTIC FIBROSIS (2019)
Validity and Reliability of a Novel Multimodal Questionnaire for the Assessment of Abdominal Symptoms in People with Cystic Fibrosis (CFAbd-Score)
Anke Jaudszus et al.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2019)
The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers
Nicola J. Rowbotham et al.
THORAX (2018)
Energy Balance and Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating Mutations
Virginia A. Stallings et al.
JOURNAL OF PEDIATRICS (2018)
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study
Margaret Rosenfeld et al.
LANCET RESPIRATORY MEDICINE (2018)
Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation
Daniel Gelfond et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2017)
Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings
Harold Tabori et al.
PLOS ONE (2017)
Proton Pump Inhibitor Use Is Associated With an Increased Frequency of Hospitalization in Patients With Cystic Fibrosis
Fares Ayoub et al.
GASTROENTEROLOGY RESEARCH (2017)
Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression
Carmelo Scarpignato et al.
BMC MEDICINE (2016)
Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease
Benjamin Lazarus et al.
JAMA INTERNAL MEDICINE (2016)
Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study
Jane C. Davies et al.
LANCET RESPIRATORY MEDICINE (2016)
Continuous Proton Pump Inhibitor Therapy and the Associated Risk of Recurrent Clostridium difficile Infection
Emily G. McDonald et al.
JAMA INTERNAL MEDICINE (2015)
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Bonnie W. Ramsey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation
Frank J. Accurso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Share Paper
